WO2011062458A3 - Composition containing homoisoflavanone as active ingredient for preventing and treating obesity or metabolic syndrome - Google Patents

Composition containing homoisoflavanone as active ingredient for preventing and treating obesity or metabolic syndrome Download PDF

Info

Publication number
WO2011062458A3
WO2011062458A3 PCT/KR2010/008283 KR2010008283W WO2011062458A3 WO 2011062458 A3 WO2011062458 A3 WO 2011062458A3 KR 2010008283 W KR2010008283 W KR 2010008283W WO 2011062458 A3 WO2011062458 A3 WO 2011062458A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
homoisoflavanone
preventing
metabolic syndrome
active ingredient
Prior art date
Application number
PCT/KR2010/008283
Other languages
French (fr)
Korean (ko)
Other versions
WO2011062458A2 (en
Inventor
권혁상
고종희
유종수
윤종민
장현수
유정수
연승우
강재훈
Original Assignee
일동제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일동제약주식회사 filed Critical 일동제약주식회사
Publication of WO2011062458A2 publication Critical patent/WO2011062458A2/en
Publication of WO2011062458A3 publication Critical patent/WO2011062458A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a composition for preventing and treating obesity, obesity-related complications or metabolic syndrome, containing homoisoflavanone or a pharmaceutically acceptable salt thereof as an active ingredient. More specifically, the present invention relates to: a pharmaceutical composition for preventing and treating obesity, obesity-related complications or metabolic syndrome by inhibiting differentiation of adipocytes and maintaining a high level of SIRT1, thereby reducing bodyweight, abdominal fat and glucose tolerance; a method for preventing and treating same comprising the step of administering to a subject in need thereof an effective amount of homoisoflavanone or a pharmaceutically acceptable salt thereof; and uses of homoisoflavanone or a pharmaceutically acceptable salt thereof for the preparation of a therapeutic agent. The composition of the present invention inhibits differentiation of adipocytes and maintains a high level of SIRT1, thereby reducing bodyweight, abdominal fat and glucose tolerance, and can thus be useful for the prevention and treatment of obesity, obesity-related complications or metabolic syndrome.
PCT/KR2010/008283 2009-11-23 2010-11-23 Composition containing homoisoflavanone as active ingredient for preventing and treating obesity or metabolic syndrome WO2011062458A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090113119A KR101157028B1 (en) 2009-11-23 2009-11-23 Composition comprising the homoisoflavanone for preventing or treating of obesity or metabolic syndrome
KR10-2009-0113119 2009-11-23

Publications (2)

Publication Number Publication Date
WO2011062458A2 WO2011062458A2 (en) 2011-05-26
WO2011062458A3 true WO2011062458A3 (en) 2011-11-03

Family

ID=44060220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/008283 WO2011062458A2 (en) 2009-11-23 2010-11-23 Composition containing homoisoflavanone as active ingredient for preventing and treating obesity or metabolic syndrome

Country Status (2)

Country Link
KR (1) KR101157028B1 (en)
WO (1) WO2011062458A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101973792B1 (en) * 2010-04-30 2019-05-02 일동제약(주) Composition comprising the homoisoflavanone for preventing or treating of dementia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020033336A (en) * 2000-10-30 2002-05-06 박선민 Food composition comprising extract from Polygonatum odoratum (Mill.) Druce
KR100416650B1 (en) * 2000-10-19 2004-02-05 신동수 Extract Polygonatum and composition caontaining the same with hypocholesterolemic and hypoglycemic activities

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100416650B1 (en) * 2000-10-19 2004-02-05 신동수 Extract Polygonatum and composition caontaining the same with hypocholesterolemic and hypoglycemic activities
KR20020033336A (en) * 2000-10-30 2002-05-06 박선민 Food composition comprising extract from Polygonatum odoratum (Mill.) Druce

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAFI, M. M. ET AL.: "Identification of a structure specific Bcl-2 phosphorylating homoisoflavone molecule from Vietnamese coriander (Polygonatum odoratum) that induces apoptosis and G2/M cell cycle arrest in breast cancer cell lines", FOOD CHEMISTRY, vol. 104, 2007, pages 332 - 340, XP022040352, DOI: doi:10.1016/j.foodchem.2006.11.045 *

Also Published As

Publication number Publication date
WO2011062458A2 (en) 2011-05-26
KR101157028B1 (en) 2012-07-19
KR20110056686A (en) 2011-05-31

Similar Documents

Publication Publication Date Title
WO2011107755A3 (en) Immediate/delayed drug delivery
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2011107750A3 (en) Delayed prolonged drug delivery
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2012033792A3 (en) Treatment of diseases
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
EP3434687A3 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
WO2007108990A3 (en) Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
MX2009004681A (en) Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors.
WO2012007159A3 (en) Novel gastro-retentive dosage forms
WO2011041632A3 (en) Combination therapies for the treatment of obesity
WO2010087565A3 (en) Novel use of piperine
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
EP2490700A4 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
GB2476202A (en) Novel choline cocrystal of epalrestat
WO2010045417A3 (en) Combination therapies for the treatment of obesity
WO2011074015A3 (en) Composition of pharmaceutical product to treat sexual dysfunction
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
WO2010151503A3 (en) Combination therapies for the treatment of obesity
WO2011159100A3 (en) Anti-cancer pharmaceutical composition
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2011126342A3 (en) Novel use of polygonatum falcatum or polygonatum sibiricum extract
WO2018093237A3 (en) Composition comprising formic acid or pharmaceutically acceptable salt thereof as active ingredient for preventing or treating obesity or metabolic syndromes caused by obesity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10831825

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10831825

Country of ref document: EP

Kind code of ref document: A2